Sentence examples for molecular subtypes described from inspiring English sources

Thus, the wild-type GIST molecular subtypes described herein may represent distinct clinical entities, so that their definition provides the foundation for further studies that could provide insights into improved tailored therapy and clinical management of GIST.

Breast cancer is a highly heterogenous disease at the morphologic and molecular level, with at least four main molecular subtypes described, including luminal (divided into luminal A and B), HER2 over-expressing, and basal-like [ 1– 3].

Each of the intrinsic molecular subtypes described for invasive breast cancer can be identified in DCIS, though there are differences in the relative frequency of subgroups, in particular, the triple negative and basal-like phenotype is very uncommon in DCIS.

In relation to breast cancer molecular subtypes described by Sorlie et al. [ 31], Msx2 mRNA expression was particularly low in the basal subtype and high in the luminal B and Her2 subtypes of breast cancer (P = 0.001).

The intrinsic gene list was used to appoint the samples to molecular subtypes as described [ 12].

For this purpose we calculated the correlation coefficient between the gene-expression profiles of the 97 triple-negative tumors and the centroids of the five molecular subtypes as described previously by Hu et al. [ 3].

Based on the IHC measurement, breast cancer cases were categorized into four different molecular subtypes as described elsewhere: luminal type A (ER + and/or PR +, HER2 -: Luminal A), luminal type B (ER + and/or PR +, HER2 +: Luminal B), Her2 overexpressed (ER - and PR -, HER2 +: HER2), and triple negative (ER -/PR -/HER2 -: TNBC) [ 19].

The specific characteristics of each molecular subtype are described below and are summarized in Figure 2. The smallest cluster of 9 tumors (cluster A, marked red in Figure 1) differed most strongly from all other tumors (Figure 1B).

Over the years, other molecular subtypes have been described, such as claudin low and molecular apocrine tumors.

For each sample, molecular subtypes were defined as described above (Supplementary Table 5).

In breast cancer, five molecular subtypes have been repeatedly described in non-IBC [ 30- 32], and these subtypes have been strongly associated with clinical outcome and drug sensitivity.